Gena Wang
Stock Analyst at Barclays
(2.21)
# 2,602
Out of 4,784 analysts
197
Total ratings
38.17%
Success rate
-3.89%
Average return
Main Sectors:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Maintains: Overweight | $63 → $57 | $31.60 | +80.38% | 2 | Feb 28, 2025 | |
| VIR Vir Biotechnology | Maintains: Overweight | $26 → $31 | $6.70 | +362.69% | 6 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $55 → $26 | $8.07 | +222.18% | 7 | Feb 28, 2025 | |
| MRNA Moderna | Downgrades: Equal-Weight | $111 → $45 | $31.12 | +44.60% | 8 | Feb 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $56 | $36.99 | +51.39% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $435 → $467 | $492.69 | -5.21% | 16 | Feb 11, 2025 | |
| BLUE bluebird bio | Maintains: Overweight | $2 → $40 | $4.08 | +880.39% | 10 | Dec 31, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $5 → $3 | $1.25 | +140.00% | 9 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $45 → $56 | $54.24 | +3.24% | 14 | Dec 3, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $3 → $4 | $2.91 | +37.46% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $9 | $0.82 | +997.56% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $1.27 | +293.70% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $8 | $7.86 | +1.78% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $268.46 | +22.55% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $71.44 | +20.38% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $4.32 | +247.22% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $70.41 | +188.31% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $31 | $22.21 | +39.58% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $7.83 | +538.57% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $37.82 | +114.17% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $31.15 | +63.72% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.63 | +1,139.67% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $35.06 | +168.11% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $12.37 | -27.24% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $11.58 | +115.89% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.33 | +145.57% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.95 | +15.11% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.14 | +186.62% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.97 | +5,433.20% | 1 | Jan 6, 2017 |
Avidity Biosciences
Feb 28, 2025
Maintains: Overweight
Price Target: $63 → $57
Current: $31.60
Upside: +80.38%
Vir Biotechnology
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $6.70
Upside: +362.69%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $8.07
Upside: +222.18%
Moderna
Feb 18, 2025
Downgrades: Equal-Weight
Price Target: $111 → $45
Current: $31.12
Upside: +44.60%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $55 → $56
Current: $36.99
Upside: +51.39%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $492.69
Upside: -5.21%
bluebird bio
Dec 31, 2024
Maintains: Overweight
Price Target: $2 → $40
Current: $4.08
Upside: +880.39%
Editas Medicine
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.25
Upside: +140.00%
PTC Therapeutics
Dec 3, 2024
Maintains: Equal-Weight
Price Target: $45 → $56
Current: $54.24
Upside: +3.24%
Kodiak Sciences
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $2.91
Upside: +37.46%
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $0.82
Upside: +997.56%
Nov 5, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $1.27
Upside: +293.70%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $7.86
Upside: +1.78%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $268.46
Upside: +22.55%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $71.44
Upside: +20.38%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $4.32
Upside: +247.22%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $70.41
Upside: +188.31%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $22.21
Upside: +39.58%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $7.83
Upside: +538.57%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $37.82
Upside: +114.17%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $31.15
Upside: +63.72%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $3.63
Upside: +1,139.67%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $35.06
Upside: +168.11%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $12.37
Upside: -27.24%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $11.58
Upside: +115.89%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.33
Upside: +145.57%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.95
Upside: +15.11%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.14
Upside: +186.62%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.97
Upside: +5,433.20%